Valneva: 2024 sales up 10%

(CercleFinance.com) - Valneva reports a 10% increase in sales to E169.
6m for 2024, including sales growth of 13% to E163.3m, thus meeting its targets, despite lower-than-expected sales of Ixchiq in the US.

It also boasts a solid cash position of E168.3m at end-2024, as well as progress, enabling it to anticipate the announcement of various clinical results, product approvals and potential indication expansions in 2025.

For 2025, the vaccines company anticipates sales of E170m to E180m, sales of E180m to E190m, and operating cash consumption of under E30m, compared with over E60m last year.


Copyright (c) 2025 CercleFinance.com. All rights reserved.